PCG
RXRX icon

Private Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Private Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-196
Closed -$1K – 2072
2022
Q1 		$1K Buy
196
+111
+131% +$1.18K ﹤0.01% 1993
2021
Q4 		$2K Buy
+85
New +$1.6K ﹤0.01% 1835

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DOFI
DCVC Opportunity Fund II Palo Alto, California $17.2M AUM 22.94% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Private Capital Group's RXRX Position: Q2 2022 in Review

Private Capital Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 196 shares — an estimated $1K sold.

Private Capital Group first reported a position in RXRX in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

  • Private Capital Group reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 196 Recursion Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Private Capital Group first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Private Capital Group's Recursion Pharmaceuticals position peaked at $2K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.